Should I buy or sell Galmed Pharmaceuticals stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Galmed Pharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" GLMD shares. View GLMD analyst ratings or view top-rated stocks .

How have GLMD shares performed in 2023?

Galmed Pharmaceuticals' stock was trading at $7.50 at the beginning of the year. Since then, GLMD shares have decreased by 95.2% and is now trading at $0.3630. View the best growth stocks for 2023 here .

Are investors shorting Galmed Pharmaceuticals?

Galmed Pharmaceuticals saw a increase in short interest in November. As of November 15th, there was short interest totaling 12,900 shares, an increase of 17.3% from the October 31st total of 11,000 shares. Based on an average trading volume of 165,600 shares, the short-interest ratio is currently 0.1 days. Approximately 0.4% of the shares of the stock are sold short. View Galmed Pharmaceuticals' Short Interest .

When is Galmed Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 3rd 2024. View our GLMD earnings forecast .

How were Galmed Pharmaceuticals' earnings last quarter?

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) posted its earnings results on Thursday, June, 1st. The biopharmaceutical company reported ($1.09) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.50) by $0.41.

When did Galmed Pharmaceuticals' stock split?

Galmed Pharmaceuticals's stock reverse split before market open on Monday, May 15th 2023. The 1-15 reverse split was announced on Monday, May 15th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, May 15th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What other stocks do shareholders of Galmed Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Galmed Pharmaceuticals investors own include OPKO Health (OPK) , Viking Therapeutics (VKTX) , SCYNEXIS (SCYX) , Sorrento Therapeutics (SRNE) , Rite Aid (RAD) , Exelixis (EXEL) , Ocular Therapeutix (OCUL) , TG Therapeutics (TGTX) , TherapeuticsMD (TXMD) and Corbus Pharmaceuticals (CRBP) .

Who are Galmed Pharmaceuticals' major shareholders?

Galmed Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include Walleye Capital LLC (14.87%) and Concourse Financial Group Securities Inc. (0.00%).

How do I buy shares of Galmed Pharmaceuticals?

Shares of GLMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Galmed Pharmaceuticals Stock Price, News & Analysis (NASDAQ:GLMD)

$0.36

-0.01 (-1.37%)

(As of 01:16 PM ET)

Compare

Today's Range: $0.34
▼
$0.38
50-Day Range: $0.29
▼
$0.66
52-Week Range: $0.26
▼
$14.18

Volume: 163,309 shs
Average Volume: 133,266 shs
Market Capitalization: $604,800.00

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

About Galmed Pharmaceuticals Stock (NASDAQ:GLMD)

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel.

GLMD Stock Price History

30 days | 90 days | 365 days | Advanced Chart

GLMD Stock News Headlines

November 24, 2023 | americanbankingnews.com

Galmed Pharmaceuticals (NASDAQ:GLMD) Coverage Initiated at StockNews.com

November 20, 2023 | finance.yahoo.com

Galmed Announces a delay in the initiation of its Primary Sclerosing Cholangitis (PSC) Phase 2a Study

November 29, 2023 | Autonomix (Ad)

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com

November 4, 2023 | morningstar.com

Galmed Pharmaceuticals Ltd GLMD

September 26, 2023 | finance.yahoo.com

Galmed Announces Allowance of New Patent for Aramchol for the Treatment of Pulmonary and Dermal Fibrosis

August 3, 2023 | nasdaq.com

Galmed Pharmaceuticals (GLMD) Price Target Increased by 300.00% to 4.08

July 14, 2023 | marketwatch.com

Galmed Pharma Shares Drop 30% After Public Offering Prices

July 14, 2023 | seekingalpha.com

Galmed shares slump on pricing discounted stock and warrants offering

November 29, 2023 | Autonomix (Ad)

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

July 14, 2023 | finance.yahoo.com

Galmed Pharmaceuticals Announces Pricing of $7 Million Public Offering

July 13, 2023 | investorplace.com

Why Is Galmed Pharmaceuticals (GLMD) Stock Moving Today?

July 10, 2023 | finance.yahoo.com

Galmed to employ OnKai's disruptive Artificial Intelligence (AI) in its Planned Phase 2a Clinical Trial in PSC

July 3, 2023 | bizjournals.com

Madrigal begins process seeking OK for multibillion-dollar — yet elusive — NASH drug

June 3, 2023 | benzinga.com

Galmed Pharmaceuticals Stock (NASDAQ:GLMD), Insider Trading Activity

June 1, 2023 | finanznachrichten.de

Galmed Pharmaceuticals Ltd.: Galmed Pharmaceuticals Reports First Quarter 2023 Financial Results and Recent Developments

June 1, 2023 | msn.com

Recap: Galmed Pharmaceuticals Q1 Earnings

June 1, 2023 | finance.yahoo.com

Galmed Pharmaceuticals Reports First Quarter 2023 Financial Results and Recent Developments

May 17, 2023 | thestreet.com

Why Galmed Pharmaceuticals (GLMD) Stock Is Surging Today

May 11, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Galmed Pharmaceuticals (GLMD) and Haemonetics (HAE)

May 9, 2023 | finance.yahoo.com

Galmed Announces Initiation of a Clinical Development Program to Evaluate Aramchol meglumine for the Treatment of Primary Sclerosing Cholangitis (PSC)

May 5, 2023 | msn.com

Why Is Galmed Pharmaceuticals (GLMD) Stock Up 37% Today?

May 4, 2023 | finance.yahoo.com

Galmed Pharmaceuticals forms a Strategic Partnership with OnKai

March 29, 2023 | finance.yahoo.com

Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2022

February 17, 2023 | seekingalpha.com

GLMD Galmed Pharmaceuticals Ltd.

February 8, 2023 | finance.yahoo.com

Galmed Announces Issuance of New Composition of Matter Patent for Aramchol meglumine Salt

January 6, 2023 | finance.yahoo.com

Can Galmed Pharmaceuticals (NASDAQ:GLMD) Afford To Invest In Growth?

January 4, 2023 | marketwatch.com

Galmed Pharmaceuticals Shares Up 9.2% on Data From Liver Treatment Aramchol Study

See More Headlines

Receive GLMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Galmed Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 6/01/2023
Today: 11/29/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 4/03/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:GLMD
CUSIP: N/A
CIK: 1595353
Web: www.galmedpharma.com
Phone: (723) 693-8448
Fax: 972-3693-8447
Employees: 4
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($3.7793)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-17,870,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -58.61%
Return on Assets: -48.40%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 6.79
Quick Ratio: 3.59

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $9.20 per share
Price / Book: 0.04

Miscellaneous

Outstanding Shares: 1,680,000
Free Float: 1,347,000
Market Cap: $609,840.00
Optionable: Not Optionable
Beta: 0.95

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

Mr. Allen Baharaff (Age 58)
Co-Founder, President, CEO & Chairman
Comp: $803.5k
Mr. Doron Cohen (Age 56)
Chief Financial Officer
Comp: $175.33k
Mr. Guy Nehemya (Age 38)
COO & Data Protection Officer
Comp: $235.56k
Mr. Yohai Stenzler CPA (Age 40)
Chief Accounting Officer
Comp: $239.48k
Dr. Liat Hayardeny (Age 56)
Chief Scientific Officer
Comp: $125.24k
Ms. Yael Hollander (Age 40)
Vice President of Legal Affairs & Strategy
Comp: $134.21k
Ms. Shani Ganon
Human Resources Manager
Dr. Tali Gorfine (Age 53)
Medical Consultant
Comp: $202.76k

Key Competitors

View All Competitors

Institutional Ownership

Walleye Capital LLC
Bought 249,763 shares on 11/21/2023
Ownership: 14.867%

View All Institutional Transactions

GLMD Stock Analysis - Frequently Asked Questions

Should I buy or sell Galmed Pharmaceuticals stock right now?: 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Galmed Pharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" GLMD shares.
View GLMD analyst ratings or view top-rated stocks.
How have GLMD shares performed in 2023?: Galmed Pharmaceuticals' stock was trading at $7.50 at the beginning of the year. Since then, GLMD shares have decreased by 95.2% and is now trading at $0.3630.
View the best growth stocks for 2023 here.
Are investors shorting Galmed Pharmaceuticals?: Galmed Pharmaceuticals saw a increase in short interest in November. As of November 15th, there was short interest totaling 12,900 shares, an increase of 17.3% from the October 31st total of 11,000 shares. Based on an average trading volume of 165,600 shares, the short-interest ratio is currently 0.1 days. Approximately 0.4% of the shares of the stock are sold short.
View Galmed Pharmaceuticals' Short Interest.
When is Galmed Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 3rd 2024.
View our GLMD earnings forecast.
How were Galmed Pharmaceuticals' earnings last quarter?: Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) posted its earnings results on Thursday, June, 1st. The biopharmaceutical company reported ($1.09) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.50) by $0.41.

When did Galmed Pharmaceuticals' stock split?: Galmed Pharmaceuticals's stock reverse split before market open on Monday, May 15th 2023. The 1-15 reverse split was announced on Monday, May 15th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, May 15th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.
What other stocks do shareholders of Galmed Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Galmed Pharmaceuticals investors own include OPKO Health (OPK), Viking Therapeutics (VKTX), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Rite Aid (RAD), Exelixis (EXEL), Ocular Therapeutix (OCUL), TG Therapeutics (TGTX), TherapeuticsMD (TXMD) and Corbus Pharmaceuticals (CRBP).
Who are Galmed Pharmaceuticals' major shareholders?: Galmed Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include Walleye Capital LLC (14.87%) and Concourse Financial Group Securities Inc. (0.00%).
How do I buy shares of Galmed Pharmaceuticals?: Shares of GLMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:GLMD) was last updated on 11/29/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial